C ells of the innate immune system collate environmental cues from pathogen-and damage-associated molecular patterns in tissues via pattern recognition receptors such as TLRs. Among innate immune cells, DCs are uniquely specialized to collate pattern recognition signals and to acquire, process, and present Ags to elicit helper/effector T cell responses via MHCpeptide/TCR interactions and concomitant costimulatory signals (B7/CD28). The pivotal role of dendritic cells (DCs) in controlling T cell responses is exemplified by tolerogenic DC subsets that actively suppress (regulate) T cell responses to Ags they present (1) . Thus, in some physiologic settings, DCs promote tolerogenic outcomes by presenting Ags to T cells in the context of negative costimulation via CTLA4 and programmed death-1 (PD-1) pathways (2) . Rare DCs expressing the inducible enzyme IDO also suppress innate and adaptive immune responses that can overcome the T cell stimulatory properties of other DCs in local environments such as inflamed lymph nodes (LNs) to create immune privilege (3) . Thus, distinct DC subsets exhibit considerable functional heterogeneity and DCs with T cell immune stimulatory and inhibitory functions have been described previously.
Previously, we reported that murine DCs competent to express IDO in physiologic settings were a rare DC population exhibiting attributes of both B cells (such as CD19) and DCs (4, 5) . CD19 + DCs in inflamed LNs draining local sites of tumor growth and B220 + DCs in LNs draining skin exposed to tumor promoters possessed potent and dominant T cell regulatory properties via IDO, because of their ability to activate and stabilize regulatory (Foxp3-lineage) CD4 T cell (Treg) suppression at these sites (6, 7) . Splenic CD19 + DCs do not express IDO during homeostasis, but CD19 + DCs were the only DC subset to express functional IDO in mice following treatment with soluble CTLA4 (CTLA4-Ig) and CpGs (.50 mg, i.v.) that ligate B7 and TLR9, respectively (8, 9) . Thus, FACS-sorted CD19 + DCs from CpG-treated mice mediated potent IDO-dependent T cell suppression, whereas sorted CD19
neg DCs stimulated robust T cell proliferation that was not enhanced in the presence of IDO inhibitors. Autocrine or paracrine signaling via IFN type I receptors (IFNARs) was essential for IDO induction in CD19 + DCs following B7 or TLR9 ligation (10) . In this paper, we show that high-dose CpG treatment induced dominant regulatory responses via IDO in all peripheral lymphoid tissues and describe the cellular and molecular factors required for this rapid response to in vivo TLR9 ligation.
Materials and Methods

Mice
All mice were bred in a specific pathogen-free facility, and the local (Georgia Health Sciences University) Institutional Animal Care and Use Committee approved all procedures involving mice. OT-1 (C57BL/6 [B6]), A1 (CBA), and BM3 (CBA) TCR transgenic mice used as sources of responder T cells in suppression assays were described previously (11) . Mice deficient in PD-1 and PD-ligand (PD-L) PD-[L1+L2] genes (12) and Foxp3-GFP knockin mice (13) were described previously, and colonies were maintained at Georgia Health Sciences University. Mice with defective RAG-1, TCRbg, and B7.1/2 genes were purchased from The Jackson Laboratory (Bar Harbor, ME). Except where indicated, all mice had B6 backgrounds.
CpG oligonucleotides
CpG-B (number 1826; 59-TCCATGACGTTCCTGACGTT-39) and CpG-C (number 2395; 59-TCGTCGTTTTCGGCGCGCGCCG-39) with fully phosporothioate backbones were a gift from Coley Pharmaceuticals (Ottawa, ON, Canada). Mice were injected with CpGs (25 or 100 mg/mouse, i.v.) as described previously (9, 14) , and spleens were harvested 24 h (genedeficient mice) or 42 h (mAb-treated mice) after CpG treatment; untreated and isotype mAb-pretreated B6 mice were included as positive controls for T cell suppression in every experiment.
1-Methyl-D-tryptophan
1-Methyl-D-tryptophan (D-1MT) (clinical grade, a gift from Newlink Genetics, Ames, IA) was prepared as a 20 mM stock solution in 0.1 M NaOH, adjusted to pH 7.4, and stored at 220˚C protected from light. D-1MT was added to MLRs at a final concentration of 200 mM (9, 14) . mAb blockade mAbs specific for mouse TGF-b (number 1835, clone 1D11; R&D Systems), CTLA4 (number 553719; BD Biosciences), PD-1 (number 55189, clone J43, CD273; BD Biosciences), PD-L1 (clone MIH7), and PD-L2 (clone TY25) were injected (i.p., 100 or 500 mg anti-TGF-b mAb) 6 h before CpG treatment. PD-L1 and PD-L2 mAbs were described previously (6) . Control mice were pretreated with isotype-matched mAbs with irrelevant specificities.
MACS enrichment
MACS enrichment for splenic DCs (CD11c + ) and Tregs (CD4 + CD25 + ) was performed according to the manufacturer's instructions (Magnetic Cell Separation Technology [MACS]; Miltenyi Biotec, Auburn, CA), except that cells were incubated with mAb beads at room temperature, and DC bead conjugates were passed over columns twice. As previously described, IDO-expressing CD19 + DCs (7, 9) and IDO-activated Tregs (6, 14) mediate dominant suppression ex vivo that overcomes the T cell stimulatory effects of a large excess of other DCs and activated T cells, respectively, such that it is not necessary to purify these cell types by flow cytometric methods to detect their T cell-suppressive functions. Typically, MACS separation resulted in ∼25-fold enrichment of CD19 + DCs (∼5% of selected cells) and selected CD4 + CD25 + Tregs were .80% pure. ; all from Pharmingen-BD Biosciences, San Jose, CA) and analyzed using a FACSCalibur or FACSCanto flow cytometer (BD Biosciences). Staining to detect intracellular IL-17 and IFN-g was performed on erythrocyte-free spleen cell suspensions by staining for surface Ags (CD4) then fixing, permeabilizing, and staining to detect cytokines overnight at 4˚C as described previously (14) .
Analytical flow cytometry
Immunohistochemistry
Sections were stained for IDO using a rabbit polyclonal Ab generated using a synthetic IDO peptide as described previously (15) .
Kynurenine detection
Kynurenine was detected by HPLC analysis of lymphoid tissue lysates as described previously (16) . In brief, tissues were homogenized in PBS, supernatants were deproteinated in TCA, and 50 ml was used for HPLC (C18 reverse-phase column).
In vivo OT-2 T cell responses to OVA (6, 14) . Thymidine incorporation by responder T cells (in triplicate) was assessed after 72 h (96 h) for BM3 responders. As previously described, DCs or Tregs from untreated control mice failed to suppress T cell proliferation, and suppression mediated by rare IDO-expressing CD19 + DCs or IDO-activated Tregs predominated over the T cell stimulatory effects of other DCs or other T cells in cultures (7, 14) . DCs (or Tregs) from CpG-treated B6 mice were included as positive controls for suppression in all experiments.
Statistical analysis
Analyses of T cell proliferation data to detect suppression were performed using Student t test to compare means (61 SD) from triplicate cultures within a group. A p value , 0.1 was considered significant.
Results
Induced IDO blocks proinflammatory responses to CpGs
Previously, we reported that systemic treatment of mice with relatively high doses of TLR9 ligands (CpGs) induced functional IDO exclusively in splenic CD19 + DCs (9) . When induced to express IDO, CD19 + DCs blocked IL-6 production by DCs and activated splenic Tregs (14) . Regulatory responses in this model were critically dependent on the dose of CpGs. Thus, selective IDO expression by perifollicular CD19 + DCs was observed in mice treated with high doses of CpG (.50 mg), but no IDO + cells were detected in spleens of mice treated with lower doses of CpG (25 mg; Fig. 1A ). Consistent with these outcomes, the IDO metabolite kynurenine was detected in lysates of spleens from mice treated with high (100 mg) but not low (25 mg) doses of CpG (Fig.  1B, left panel) . Similarly, kynurenine was detected in lysates of peripheral LNs of mice treated with high but not low doses of CpG (Fig. 1B, right panel) . Thus, systemic TLR9 ligands induced IDO activity in peripheral lymphoid tissues, and IDO induction was critically dependent on the dose of CpGs administered. These data showed that IDO induction is finely tuned to the potency of TLR9 signals in all peripheral lymphoid tissues.
To elucidate potential T cell regulatory effects of TLR9-induced IDO, we evaluated local T cell responses to OVA following immunization (OVA+CFA, s.c.) of B6 mice harboring small cohorts of marked (Thy1.1 + ) OVA-specific CD4 T cells from OT-2 TCR transgenic mice. Absolute numbers of OT-2 T cells present in inguinal LNs draining the site of OVA/CFA immunization were consistently lower (∼5-fold) in mice pretreated with high doses (100 mg) of CpGs (Fig. 1C) . Moreover, the fraction of dLN OT-2 T cells that expressed intracellular IFN-g (after restimulation ex vivo) was substantially lower in mice pretreated with high doses of CpGs (N in Fig. 1C ). However, local OT-2 responses were restored to levels seen in control (OVA immunized) mice when oral IDO inhibitor D-1MT was given before CpG pretreatment. Thus, IDO induced by CpG treatment dominantly regulated OT-2 clonal expansion and differentiation in local dLNs following OVA immunization.
IDO-competence of splenic DCs is T cell dependent
To assess requirements for TLR9-mediated induction of IDO in splenic DCs, we measured the T cell stimulatory properties of DCs (MACS-enriched CD11c + ) from CpG-treated mice lacking defined lymphocyte populations. Splenic DCs from CpG-treated RAG-1-KO mice, which lack T and B cells, stimulated robust proliferation of OT-1 T cells in the presence of OVA peptide, and proliferation was not enhanced when IDO inhibitor (D-1MT) was present during culture ( Fig. 2A , n and N, respectively). As expected, splenic DCs from control CpG-treated B6 mice stimulated weak OT-1 proliferation that was enhanced significantly by adding D-1MT, revealing that IDO suppressed DC T cell stimulatory functions by 80% ( Fig. 2A) . DCs from CpG-treated TCRbg-KO mice, which have B cells but lack T cells, also failed to suppress ex vivo OT-1 T cell responses via IDO (Fig. 2B) .
In a previous study, we reported that IDO-competent DCs developed and functioned normally in spleens of B cell-deficient (mMT-KO, J H -KO) mice despite their close relationship to B cells (5) . Thus, the ability of splenic DCs to express functional IDO in response to TLR9 ligands was abrogated when T cells were developmentally ablated, suggesting that IDO competence in splenic DCs depended on interactions with T cells.
Next, we identified molecular signals that maintain IDO competence in splenic DCs. As with T cell-deficient mice, mice with defective B7.1 and B7.2 (CD80 and CD86) genes (B7.1/2-KO mice) yielded splenic DCs that stimulated robust OT-1 T cell responses after high-dose CpG treatment, and D-1MT had no effect on elicited responses (Fig. 2C) . Thus, intact costimulatory pathways via B7.1 and B7.2 were essential for DCs to acquire competence to express IDO in response to TLR9 ligands.
Previous studies revealed that TGF-b (19) and cells expressing surface CTLA4 (11, 20) stimulated DCs to express IDO. To test whether TGF-b and CTLA4 signals were required for IDO competence to TLR9 ligands, we used mAbs (i.p.) to block TGF-b and CTLA4 signaling during responses to CpGs. Treatments with anti-TGF-b (500 mg) and anti-CTLA4 (CD152; 100 mg) mAbs 6 h before CpG treatment yielded splenic DCs with potent T cell stimulatory properties that were not enhanced by IDO inhibitor (Fig. 2D, 2E, respectively) . In each case, DCs from B6 mice treated with isotype-matched mAbs treatment mediated potent suppression via IDO because of TLR9 ligation. Thus, nonredundant signals via TGF-b and costimulatory pathways were essential for regulatory responses via IDO in splenic DCs following TLR9 ligation. Moreover, these signals were required constitutively
IDO competence in splenic DCs is PD-1 and PD-L dependent
PD-1 and its ligands PD-L1 and PD-L2 mediate negative costimulation that blocks T cell effector functions and promotes T cell death. To test whether PD-1/PD-L interactions were required for IDO competence in splenic DCs, we evaluated the effects of PD-1/ PD-L ablation on IDO induction in DCs after CpG treatment. Pretreatment with anti-PD-1 blocking mAb (Fig. 3A) and PD-1 gene ablation (Fig. 3B ) eliminated T cell regulatory responses via IDO in DCs. Likewise, pretreatment with mixtures (50:50) of both anti-PD-L1 and anti-PD-L2 mAbs (Fig. 3C ) and genetic ablation of both PD-L1 and PD-L2 genes (PD-[L1+L2]-KO mice; Fig. 3D ) abrogated T cell regulatory responses via IDO to CpG treatment. Thus, intact PD-1 and PD-L1/2 pathways were essential for DCs to acquire T cell suppressor activity via IDO after TLR9 ligation. Analyses of splenic DCs in mice with defective PD-1 and PD-L1/ PD-L2 genes revealed no significant differences in the relative proportions of DCs among splenocytes and CD19 + DCs among total splenic DCs (Supplemental Fig. 1 ), suggesting that the profound functional changes in DC responses to TLR9 ligation in these mice were not caused by failure of CD19 + DCs to develop per se. In accordance with previous reports (21) , flow cytometric analyses of PD-1 expression by splenic CD4 + T cells and of PD-L1 and PD-L2 expression by splenic DCs revealed that ∼50% of resting splenic Tregs and CD4 + T cells expressed PD-1 in untreated mice, whereas almost all DCs expressed PD-L1, and no DCs expressed PD-L2 (Supplemental Fig. 2) . Moreover, PD-1, PD-L1, and PD-L2 expression patterns on splenic CD4 + cells and DCs did not change substantially 24 h after CpG treatment (data not shown).
Loss of IDO-dependent T cell-suppressive functions may arise because of transcriptional or posttranslational blockade of gene expression or IDO enzyme activity, respectively. We stained spleen sections to assess whether DCs expressed IDO protein after CpG treatment. No IDO-expressing DCs were detected in spleens from RAG-1-KO mice (Fig. 4B) and from B6 mice pretreated with anti-PD-1 mAb (Fig. 4C) and mixtures (50:50) of anti-PD-L1 and anti-PD-L2 mAbs (Fig. 4D) . As expected, pretreatment with isotype-matched mAbs had no effect on CpG-induced IDO expression by DCs in perifollicular regions (Fig. 4A) . These outcomes were consistent with outcomes from DC suppression assays (Figs. 2, 3) , indicating that signals required for IDO competence in splenic DCs regulated IDO gene expression.
Treg activation after TLR9 ligation depends on costimulation to induce IDO in DCs
Previously, we reported that splenic Tregs activated rapidly (within 12-18 h) after high-dose CpG treatment because of IDO induction in CD19 + DCs (14) . To test whether TLR9-induced Treg activation was abrogated by interventions that prevented IDO induction, we assessed the functional status of splenic Tregs using an assay that detects suppressor activity of Tregs after activation in vivo (6, 14) . Graded numbers of MACS-enriched Tregs from CpG-treated mice were added to cultures containing responder T cells from A1 TCR transgenic mice (CD4, male H-Y specific, and H-2E k restricted), stimulatory APCs (CBA female), and cognate (male H-Y) peptide; in this assay, Tregs must be activated in vivo because Tregs do not activate during culture (6, 14) . Consistent with our previous findings (14) , induced Treg suppressor activity was potent because 1250 Tregs from CpG-treated B6 mice suppressed A1 T cell proliferation completely (Treg:effectors = 1:40; Fig. 5A , closed symbols). In addition, Treg suppression was abrogated completely in parallel cultures containing a mixture of anti-PD-1, anti-PD-L1, and anti-PD-L2 blocking mAbs (data not shown); PD-1/PD-L-dependent suppression ex vivo is a hallmark feature of IDO-activated Tregs from tumor dLNs and from spleen after TLR9 ligation (6, 14) . Tregs from untreated B6 mice did not mediate suppression ex vivo (data not shown), confirming that suppressive functions were acquired in vivo following CpG treatment and not during culture.
In striking contrast to the potent suppressor functions of Tregs from CpG-treated B6 mice, Tregs from CpG-treated PD-1-KO mice did not suppress A1 T cell proliferation, even when eight times more (10 4 ) Tregs were added to cultures (Fig. 5A , open symbols). Tregs from CpG-treated PD-[L1+L2]-KO mice also failed to mediate suppression (Fig. 5B) . Moreover, acute blockade of PD-1 and PD-L1+L2 interactions by injecting mAbs just before CpG treatment prevented splenic Tregs from acquiring potent suppressor activity (Fig. 5D, 5E , respectively). Likewise, Tregs from mice pretreated with anti-CTLA4 mAb before CpGtreatment did not mediate suppression (Fig. 5C ). In each case, pretreatment with isotype-matched mAbs had no effect on activation of Treg suppression following TLR9 ligation. These data support the hypothesis that molecular pathways required for IDO induction in DCs are also essential for Treg activation after TLR9 ligation.
Costimulatory blockade to prevent IDO induction allows CpGs to activate CD4 T cells
TLR9 ligands promote rapid production of proinflammatory cytokines by innate immune cells and activated effector T cells. Previously, we reported that IDO coinduced after high-dose CpG treatment blocked TLR9-induced IL-6 expression by pDCs and prevented reprogramming of Foxp3-lineage Tregs to express the proinflammatory cytokines IL-17, IFN-g, IL-2, and TNF-a (14) .
To test the hypothesis that costimulatory signals block proinflammatory cytokine expression in CD4 T cells, we assessed expression of intracellular IL-17 in gated splenic CD4 + T cells following high-dose CpG treatment. As previously reported, highdose CpG treatment did not stimulate CD4 T cells to express IL-17 in IDO-sufficient B6 mice (Fig. 6A) , whereas rapid and uniform IL-17 expression was observed in CD4 + CD25 + T cells in CpG-treated IDO1-deficient (IDO1-KO) mice (Fig. 6B) . Pretreating B6 mice with anti-PD-1 (Fig. 6C) or mixtures of anti-PD-L1 + anti-PD-L2 mAbs (Fig. 6D) 
Discussion
Previously, we reported that systemic administration of relatively high doses of CpGs induced splenic CD19 + DCs to express functional IDO; consequently, CD19 + DCs acquired potent T cell regulatory properties, including the ability to activate Tregs rapidly (5, 9, 14) . In this paper, we show that high-dose CpG treatment induced IDO activity in peripheral lymphoid tissues, which suppressed T cell responses to exogenous Ags. Moreover, IDO induction in DCs was dependent on the presence of T cells and intact costimulatory pathways, and costimulatory blockade enhanced proinflammatory responses to high-dose CpG treatment by activated CD4 T cells and Tregs. These findings reveal that the competence of DCs to express IDO and acquire regulatory phenotypes is critically dependent on the potency of TLR9 ligation and on molecular signals from T cells and Tregs. Few T cells express both PD-1 and surface CTLA4, especially during homeostasis (21, 22) . Hence, few T cell subsets are capable of interacting constitutively with CD19 + DCs to induce and stabilize IDO competence, although the possibility that different T cells provide signals via PD-1 and CTLA4 in physiologic settings cannot be excluded. During homeostasis, T cells are one of the few cell types to express PD-1, whereas all T cell subsets and many other cell types express high levels of PD-L1, and no cells express PD-L2 (21) . Approximately 50% of splenic T cells and Tregs expressed PD-1, and almost all splenic DCs-including CD19 + DCs-expressed PD-L1 (Supplemental Fig. 2 ). Thus, our findings support the hypothesis that interactions between PD-1 + T cells or Tregs and PD-L1 + CD19 + DCs are critical to maintain IDO competence in DCs. This model is consistent with studies showing that PD-L1 controls the development and regulatory functions of peripheral Tregs (12) and that IL-10 and negative costimulatory B7 ligands (B7-H1/4) maintain regulatory phenotypes of human Tregs (23), although a role for IDO in stabilizing these regulatory phenotypes was not described. Inflammatory cytokines such as IFNs, IL-2, TNF-a, and IL-10 released after TLR9 ligation expand the range of cell types expressing PD-1, PD-L1, and PD-L2 (21). Thus, opportunities for different cell types to interact via the PD-1/PD-L pathway to stimulate IDO expression in DCs are increased in settings of inflammation.
Naive T cells do not express CTLA4, but activated T cells do express CTLA4, although CTLA4 is intracellular and is not present at the (outer) cell surface. In contrast, many resting Tregs express surface CTLA4. Interactions between IDO-competent DCs and cells expressing surface CTLA4, including cloned CD4 T cells with regulatory functions, induced DCs to express functional IDO in culture (11, 20) . Thus, "reverse" signaling via the CTLA4→B7 pathway was sufficient to induce DCs to express IDO ex vivo. However, IDO enzyme activity is not detected in lymphoid tissues during homeostasis, suggesting that constitutive interactions between activated T cells and/or Tregs are insufficient to trigger IDO activity in physiologic settings and that additional signals are needed to attain signaling thresholds required for functional IDO expression in CD19 + DCs. Thus, our findings support the hypothesis that resting Tregs and/or activated T cells expressing PD-1 and surface CTLA4 mediate constitutive, subthreshold signaling that maintains the default tolerogenic potential of CD19 + DCs via IDO.
IFN-a produced after treatments with CTLA4-Ig and high-dose CpG to ligate B7 and TLR9 is one way that signaling thresholds may be breached to promote regulatory outcomes via IDO in physiologic settings (10) . Autocrine IFN-a signaling (via IFNAR/ STAT1) was obligatory to induce CD19 + DCs to express IDO after in vivo B7 or TLR9 ligation, whereas IFN-g signaling was not required for these regulatory responses (8, 9) . Additional requirements for concomitant, nonredundant signals from T cells via costimulatory pathways reveal that signaling via IFNAR alone is not sufficient for IDO competence in CD19 + DCs. Belladonna et al. (19) reported that the IDO-mediated tolerogenic phenotype of splenic CD8a + DCs was also dependent on autocrine TGF-b signaling; our finding that anti-TGF-b mAb treatment blocked TLR9-mediated IDO induction in splenic DCs is consistent with this study because CD19 + DCs coexpress CD8a (8 DCs expressing IDO are not the only regulatory mechanism that stabilizes the default regulatory status of Tregs during homeostasis as genetic IDO gene ablation in mice did not lead to spontaneous autoimmunity (15) . However, developmental ablation of IDO1 and acute pharmacologic IDO inhibition led to enhanced innate and T cell immunity in local settings of tumor growth, skin inflammation that promotes tumor progression, chronic infections, autoimmunity, and pregnancy (7, (24) (25) (26) . Thus, findings from the current study provide novel insights into a natural immune regulatory mechanism that contributes to a wide range of inflammatory syndromes of clinical significance. On the basis of these findings, we hypothesize that experimental immunotherapies targeting regulatory CTLA4 and PD-1/PD-L pathways may interfere with IDO-dependent processes that promote the tolerogenic potential of DCs and Tregs in settings of local inflammation. Moreover, the bifunctional potential of resting Tregs complicates their therapeutic use (26) . Thus, Treg ablation early in mucosal HSV infection unexpectedly led to accelerated fatal infection in mice (27) , and Treg adoptive transfer into T cell-deficient mice accelerated rather than slowed skin allograft rejection (28) . Also, reprogrammed Tregs-not naive CD4 + T cells-were the obligate source of help to prime CD8 + T cells in naive mice after OVA vaccination (29) . In this latter model, CpGs were essential to induce Treg reprogramming in LNs draining local sites of vaccine administration, suggesting that this dosing and delivery regimen avoided stimulating the IDO-dependent regulatory responses we observed in the spleen after high-dose, systemic CpG treatment. These examples emphasize the critical importance of identifying mechanisms that control how the bifunctional potential of Tregs manifests in physiologic settings of inflammation relevant to disease syndromes and immunotherapy.
In summary, our findings highlight the tight mechanistic coupling between CD19 + DCs and activated T cells and Tregs needed to maintain tolerogenic potential via IDO in physiologic settings. Although both cell types are relatively rare in physiologic settings, induction of IDO-dependent regulatory phenotypes resulted in dominant local suppression of T cell responses to exogenous Ags in peripheral lymphoid tissues draining local sites of immunization. Thus, IDO-mediated regulatory responses to high-dose CpG treatment overcame the well known proinflammatory effects of CpGs that justify their use as immune adjuvants. Numbers of CD19 + DCs may increase at sites of chronic inflammation associated with potent IDO-dependent suppression and Treg activation such as LNs draining sites of tumor growth and topical exposure to tumor promoters (4, 7). However, in our model of acute IDO induction in the spleen following high-dose CpG treatment, numbers of CD19 + DCs and Tregs did not change substantially, suggesting that collaborations between these rare cell types dominantly regulates potential proinflammatory responses by other DCs and T cell subsets following TLR9 ligation. 
